Valneva SE (VALN) Cash from Financing Activities (2021 - 2026)
Valneva SE (VALN) posted Cash from Financing Activities of -$5.5 million for Q1 2026, up 49.64% sequentially from -$10.9 million in Q4 2025, and up 6.51% YoY from -$5.2 million in Q1 2025.
Analysis
Valneva SE (VALN) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Valneva SE has reported Cash from Financing Activities for 6 years, with the latest figure at -$5.5 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 6.51% year-over-year to -$5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$195032.3 (down 100.54% YoY) and the FY2025 annual result came in at -$722871.0, down 102.18% from the prior year.
- Cash from Financing Activities grew to -$5.5 million in Q1 2026 per VALN's latest filing, from -$10.9 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $10.3 billion in Q3 2023 and troughed at -$10.3 billion in Q2 2023.
- A 5-year average of $18.7 million and a median of -$649994.6 in 2025 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 61612.28% in 2023, down 9392.38% in 2023.
- Over 5 years, Cash from Financing Activities stood at $95.4 million in 2022, then sank by 58.32% to $39.7 million in 2023, then sank by 112.34% to -$4.9 million in 2024, then tumbled by 122.23% to -$10.9 million in 2025, then soared by 49.64% to -$5.5 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$5.5 million, -$10.9 million, and -$649994.6 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | 33.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.92 Mn |
| Mar 31, 2026 | -5.49 Mn |
| Dec 31, 2025 | -10.90 Mn |
| Sep 30, 2025 | -649,994.63 |
| Jun 30, 2025 | 16.84 Mn |
| Mar 31, 2025 | -5.87 Mn |
| Dec 31, 2024 | -4.90 Mn |
| Sep 30, 2024 | 56.95 Mn |
| Jun 30, 2024 | -9.83 Mn |
| Mar 31, 2024 | -8.10 Mn |
| Dec 31, 2023 | 39.75 Mn |
| Sep 30, 2023 | 10.34 Bn |
| Jun 30, 2023 | -10.31 Bn |
| Mar 31, 2023 | -4.10 Mn |
| Dec 31, 2022 | 95.38 Mn |
| Sep 30, 2022 | 16.76 Mn |
| Jun 30, 2022 | 111.00 Mn |
| Mar 31, 2022 | 1.10 Mn |
| Dec 31, 2021 | 91.37 Mn |
| Sep 30, 2021 | -4.85 Mn |